These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 21657806

  • 1. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.
    Rubino M, Summers KH, Puenpatom A, Fu C, Ohsfeldt RL, Ben-Joseph RH.
    J Manag Care Pharm; 2011 Jun; 17(5):367-76. PubMed ID: 21657806
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Measuring economic impact of applying daily average consumption limits.
    Flavin BM, Nishida LM, Karbowicz SH, Renner ME, Leonard RJ.
    J Manag Care Pharm; 2014 Feb; 20(2):159-64. PubMed ID: 24456317
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME, Dvergsten C, Gimbel J.
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [Abstract] [Full Text] [Related]

  • 7. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study.
    Gabrail NY, Dvergsten C, Ahdieh H.
    Curr Med Res Opin; 2004 Jun; 20(6):911-8. PubMed ID: 15200750
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.
    Neil N, Merchant S, Provenzano D, Ogden K, Mody SH.
    J Med Econ; 2013 Jun; 16(2):307-17. PubMed ID: 23216013
    [Abstract] [Full Text] [Related]

  • 16. Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl.
    Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Peterson K, Ben-Joseph RH, Berner T, Summers KH.
    J Med Econ; 2012 Jun; 15(1):87-95. PubMed ID: 22032675
    [Abstract] [Full Text] [Related]

  • 17. Concomitant Filled Prescriptions of Oxymorphone or Oxycodone with CYP3A Inhibitors and Inducers.
    Coyle DT, Woodworth TS, Moeny D, Staffa J, Meyer T, Woods C, Welch EC, Haynes K, Toh S, Maro JC.
    J Manag Care Spec Pharm; 2020 May; 26(5):668-672. PubMed ID: 32347183
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.